CDTX - シダラ・セラピュ―ティクス （Cidara Therapeutics Inc.） シダラ・セラピュ―ティクスCDTXのチャート
CDTXの企業情報
| symbol | CDTx |
|---|---|
| 会社名 | Cidara Therapeutics Inc （シダラ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 シダラ・セラピューティクス（Cidara Therapeutics Inc.）（旧名：K2 Therapeutics Inc.）は抗感染製品の発見・開発・商品化に従事するバイオ企業である。同社はエキノカンジンである化合物製剤CD101を提供する。その製品はCD101静脈注射（biofungin）及びCD101トピカル（topifungin）を含む。また、免疫療法技術プラットフォーム「Cloudbreak」を所有する。同社はまた、細菌及びウイルス感染の治療用その他候補薬剤の開発を行う。CD101 IV及びCD101 topicalは前臨床開発の初期段階にある。同社の「Cloudbreak」開発候補薬剤はC001及びC016を含む。また、マウス及びモルモットにおけるC001の許容性、毒性及び薬物動態プロファイルを評価するための前臨床研究を行った。「Cloudbreak」開発候補薬剤は前臨床研究の前臨床原理証明（POP）有効性・安全性を実証した。 シダラ・セラピュ―ティクスは米国のバイオ企業。不十分な治療法による疾患のための新抗感染薬の発見、開発、実用化に焦点を当て事業を展開。CD101は抗真菌薬として実績のあるエキノカンジンであり、全身性真菌感染症の治療・予防にCD101 IV、外陰膣カンジダ症治療薬CD101 topical、流行粘膜感染症治療にCD101 VVCを開発する。 Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. |
| 本社所在地 | 6310 Nancy Ridge Drive Suite 101 San Diego CA 92121 USA |
| 代表者氏名 | Scott M. Rocklage Scott M. Rocklage |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-752-6170 |
| 設立年月日 | 41244 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 61人 |
| url | www.cidara.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cdtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -57.11200 |
| 終値（lastsale） | 4.315 |
| 時価総額（marketcap） | 119437003.665 |
| 時価総額 | 時価総額（百万ドル） 108.36520 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.07520 |
| 当期純利益 | 当期純利益（百万ドル） -69.06900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cidara Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 44% to $43.4M. Higher net loss reflects Research and development - increase of 8% to $24.1M (expense) General and administrative - increase of 8% to $5.5M (expense) Stock-based Compensation in SGA increase of 12% to $1.7M (expense). |
CDTXのテクニカル分析
CDTXのニュース
Buy Cidara Therapeutics For Data Readout And European Foothold 2023/05/21 08:41:46 Seeking Alpha
Cidara will more likely than not have success on the launch of their first drug and a mid-stage trial of their second candidate. Click here to read more.
Futures Rise As Luxury Blowout Lifts European Markets; Dollar, Yields Higher 2023/05/12 12:15:43 Zero Hedge
Futures Rise As Luxury Blowout Lifts European Markets; Dollar, Yields Higher US equity futures advanced to end the week as traders remained fixated on the path of monetary policy while assessing stronger than expected corporate earnings as the season nears its end. Contracts on the S&P 500 rose 0.3% at 8:00 a.m. ET while those on the Nasdaq 100 advanced 0.2%. Swiss luxury-goods maker Richemont soared 7.8% to a record on "spectacular sales growth", fueling a broad rally across European luxury stocks. Risk-on sentiment pushed Treasury yields higher. The Bloomberg dollar index was poised for its biggest weekly gain since March while oil prices declined again, set for their fourth weekly loss. Meanwhile, gold is also on course to end the week lower. Iron ore futures are falling sharply for a second day, but still on track for a weekly gain. In premarket trading, Tesla rose 2% after the electric-car maker raised prices of its Model X and Model S cars in the US, the third change in less than a month, while Musk announced that Twitter would have a new CEO in 6 weeks.
Recap: Cidara Therapeutics Q1 Earnings 2023/05/11 21:34:24 Benzinga
Cidara Therapeutics (NASDAQ: CDTX ) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:37 PM. Here''s what investors need to know about the announcement. Earnings Cidara Therapeutics missed estimated earnings by 25.0%, reporting an EPS of $0.03 versus an … Full story available on Benzinga.com
Cidara Therapeutics GAAP EPS of $0.03 beats by $0.07, revenue of $25.99M beats by $7.31M 2023/05/11 21:29:33 Seeking Alpha
Cidara Therapeutics press release (CDTX): Q1 GAAP EPS of $0.03 beats by $0.07.Revenue of $25.99M (+265.5% Y/Y) beats by $7.31M.
Cidara Therapeutics: Q1 Earnings Snapshot 2023/05/11 20:51:01 WTOP
SAN DIEGO (AP) — SAN DIEGO (AP) — Cidara Therapeutics Inc. (CDTX) on Thursday reported first-quarter net income of $2.5…
Cidara Therapeutics And 2 Other Stocks Under $2 Insiders Are Aggressively Buying 2023/03/28 11:50:29 Benzinga
The Dow Jones closed higher by around 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Cidara Therapeutics The Trade: Cidara Therapeutics, Inc. (NASDAQ: CDTX ) President and CEO Jeffrey Stein acquired a total 50,000 shares an average price of $1.04. To acquire these shares, it cost around … Full story available on Benzinga.com
Cidara Therapeutics''s Return On Capital Employed Overview 2023/03/24 14:46:49 Benzinga
Cidara Therapeutics (NASDAQ: CDTX ) brought in sales totaling $10.22 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 189.31%, resulting in a loss of $13.38 million. In Q3, Cidara Therapeutics earned $14.98 million, and total sales reached $40.74 million. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
Dermata, GH Research top healthcare gainers; BridgeBio, Cidara among losers 2023/03/24 14:01:43 Seeking Alpha
Dermata Therapeutics (DRMA) +40%. GH Research (GHRS) +27%. Cidara Therapeutics (CDTX) -9%. BridgeBio Pharma (BBIO) -9%. Read more here
Cidara''s Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment 2023/03/23 14:35:33 Benzinga
The FDA approved Cidara Therapeutics Inc''s (NASDAQ: CDTX ) antifungal Rezzayo (rezafungin) under priority review for treating candidemia and invasive candidiasis in adults with limited or no alternative treatment options, the company announced Wednesday. While the EMA accepted the marketing authorization application for rezafungin in August 2022, it is still under review for potential approval in Europe. Last year, Melinta Therapeutics acquired the rights to commercialize Rezzayo in the … Full story available on Benzinga.com
ZyVersa, Aziyo top healthcare gainers; Cidara, Protagenic among losers 2023/03/23 14:06:23 Seeking Alpha
ZyVersa Therapeutics (ZVSA) +33%. Aziyo Biologics (AZYO) +29%. Cidara Therapeutics (CDTX) -20%. Protagenic Therapeutics (PTIX) -19%.
Cidara Therapeutics Inc. (NASDAQ:CDTX) Is 36.51% Above Its 52-Week Low, But How Long Will It Remain So? 2022/08/13 15:30:00 Marketing Sentinel
In last trading session, Cidara Therapeutics Inc. (NASDAQ:CDTX) saw 0.42 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $0.63 trading at $0.0 or 0.79% at ring of the bell on the day assigns it a market valuation of $45.08M. That closing price of CDTX’s stock is … Cidara Therapeutics Inc. (NASDAQ:CDTX) Is 36.51% Above Its 52-Week Low, But How Long Will It Remain So? Read More »
Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M 2022/08/09 21:25:22 Seeking Alpha
Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09.Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results 2022/08/09 21:16:00 GlobeNewswire
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.
Short Volatility Alert: Cidara Therapeutics, Inc. 2022/08/05 16:23:00 Benzinga
On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX ) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72. The overall sentiment for CDTX has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 8/4/2022 with a volatility change of +85.10%. The current volatility indicator stands at 11.217. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves … Full story available on Benzinga.com
Mind-boggling stocks: Helbiz, Inc. (NASDAQ:HLBZ 4.67%), Cidara Therapeutics, Inc. (NASDAQ:CDTX -5.25%) 2022/08/02 23:48:56 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Mind-boggling stocks: Helbiz, Inc. (NASDAQ:HLBZ 4.67%), Cidara Therapeutics, Inc. (NASDAQ:CDTX -5.25%) appeared first on Stocks Equity .